Xeris Biopharma Holdings (XERS) Income from Continuing Operations (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Income from Continuing Operations of 2234000.0 for Q1 2026, down 79.84% on a QoQ basis from 11081000.0 in Q4 2025, and up 124.23% year-over-year from 996298.73 in Q1 2025.
Xeris Biopharma Holdings (XERS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 2234000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 124.23% year-over-year to 2234000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12008000.0 (up 126.64% YoY) and the FY2025 annual result came in at 554000.0, up 101.01% from the prior year.
- Income from Continuing Operations was 2234000.0 for Q1 2026 at Xeris Biopharma Holdings, down from 11081000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11081000.0 in Q4 2025 and bottomed at 33714000.0 in Q1 2022.
- A 5-year average of 12291941.18 and a median of 13390000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 83.12% — and 2025, when it surged 316.72%.
- Xeris Biopharma Holdings' Income from Continuing Operations stood at 12930000.0 in 2022, then dropped by 3.56% to 13390000.0 in 2023, then surged by 61.81% to 5113000.0 in 2024, then jumped by 316.72% to 11081000.0 in 2025, then sank by 79.84% to 2234000.0 in 2026.
- Business Quant data shows XERS's Income from Continuing Operations at 2234000.0 in Q1 2026, 11081000.0 in Q4 2025, and 621000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 11.08 Mn |
| Sep 30, 2025 | 621,000.00 |
| Jun 30, 2025 | -1.93 Mn |
| Mar 31, 2025 | -9.22 Mn |
| Dec 31, 2024 | -5.11 Mn |
| Sep 30, 2024 | -15.74 Mn |
| Jun 30, 2024 | -15.01 Mn |
| Mar 31, 2024 | -18.98 Mn |
| Dec 31, 2023 | -13.39 Mn |
| Sep 30, 2023 | -12.19 Mn |
| Jun 30, 2023 | -19.84 Mn |
| Mar 31, 2023 | -16.83 Mn |
| Dec 31, 2022 | -12.93 Mn |
| Sep 30, 2022 | -21.83 Mn |
| Jun 30, 2022 | -26.19 Mn |
| Mar 31, 2022 | -33.71 Mn |
| Dec 31, 2021 | -50.79 Mn |
| Sep 30, 2021 | -26.01 Mn |
| Jun 30, 2021 | -27.52 Mn |